
    
      This is a prospective, post-market, open label, follow-up multicenter study with patients who
      participated in the Straumann clinical study CR06/03. The total study duration for each
      patient should be 2 years.

      In total 2 visits are scheduled in this study. Bone level changes, implant success and
      survival, performance of the restorative components, and adverse events (AEs) will be
      assessed.

      The study device is a CE-marked product and FDA approved.

      Three centres, one in Portugal and two in Germany, will participate.
    
  